Business Context and Reporting Period
This Form 8-K, dated June 25, 2019, reports that AbbVie Inc. has entered into a definitive agreement to acquire Allergan plc. The transaction is structured as a recommended acquisition under Irish law via a court-sanctioned scheme of arrangement, with completion expected in early 2020 subject to regulatory and shareholder approvals.
Key Financial Metrics and Transaction Terms
- Consideration: Allergan shareholders will receive 0.8660 shares of AbbVie common stock and $120.30 in cash per Allergan share.
- Financing: AbbVie secured a $38 billion 364-day bridge credit facility to finance the cash portion of the deal and repay certain Allergan indebtedness.
- Interest Rates: The bridge facility bears interest at the base rate plus 0.0% to 1.250% or the Eurocurrency rate plus 0.750% to 2.250%, depending on AbbVie's credit rating.
- Reverse Termination Fee: AbbVie agreed to pay Allergan $1.25 billion if the transaction is terminated due to the failure to obtain antitrust approvals.
- Expense Reimbursement: Allergan agreed to reimburse AbbVie for transaction costs up to a maximum of 1% of the aggregate value of the total scheme consideration.
Material Changes and Agreements
The filing details the execution of three primary agreements on June 25, 2019: the Transaction Agreement, the Expenses Reimbursement Agreement, and the Bridge Credit Agreement. The Transaction Agreement includes standard "no-shop" provisions, requiring Allergan to use reasonable best efforts to consummate the deal and prohibiting it from soliciting alternative proposals. Upon completion, two members of Allergan's board will join AbbVie's board.
Guidance, Risks, and Contingencies
- Conditions to Closing: The acquisition is contingent upon Allergan shareholder approval, sanction by the Irish High Court, and receipt of necessary regulatory approvals.
- Termination Rights: Either party may terminate if the scheme is not effective by June 25, 2020 (extendable to September 25, 2020), if shareholder approvals are not obtained, or if a court permanently enjoins the transaction.
- Forward-Looking Statements: The filing explicitly states that no profit forecasts or asset valuations are provided. Actual results may differ materially due to integration risks, regulatory hurdles, and market conditions.
- Alternative Structure: AbbVie reserves the right to implement the acquisition via a takeover offer instead of a scheme of arrangement.
Investor Verification Checklist
- Verify the status of regulatory approvals required for the cross-border acquisition.
- Monitor the outcome of the Allergan shareholder vote on the scheme of arrangement.
- Assess the impact of the $38 billion bridge facility on AbbVie's leverage and credit rating.
- Review the specific conditions under which the $1.25 billion reverse termination fee would be triggered.
- Confirm the final exchange ratio and cash consideration, noting they are subject to adjustment.